Belle Lin

What do you make of the latest wave of young AI founders?

If you're a listener on Spotify, leave us a comment with your thoughts.

Coming up, China has become a leader in biotech, and that's affecting drug makers and pharmaceutical firms here in the US.

We dig into these shifting dynamics after the break.

Biotechnology is an incredibly competitive, research-driven field.

Meaningful advancements can mean breakthrough drugs and potentially billions of dollars for their manufacturers.

While the US has long been the leading player in biotech, China has become increasingly innovative in the space.

And that means American research firms and pharma companies can't afford not to pay attention.

WSJ reporter Peter Loftus joins us now to talk about China's rise in biotech and how U.S.

companies are reacting to the power shift.

So, Peter, you write that not too long ago, China was not a major player in drug research and development, and its companies were mainly making things like pharmaceutical ingredients or generic drugs.

What changed?

What are some of the pharmaceutical or research areas where China has shown that it has a true advantage?

And what kind of implications does China's biotech prowess have for U.S.

drug makers?

And from a geopolitical lens, why are there now also national security concerns associated with China's advancements?

Are China's advancements changing anything about how and which drugs are developed in the United States?

That was WSJ reporter Peter Loftus.

And that's it for Tech News Briefing.

If you're a listener on Spotify, be sure to leave us a comment.